Patent intelligence · US
US 10307444
Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
Patent details — US 10307444
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 4, 2019
- Expiration
- May 30, 2039
- Claims
- 21
- CPC classes
- A61K, A61K35/30, A61K35/545, A61P
Quick answer
US 10307444 (Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells) is held by Astellas Institute for Regenerative Medicine. Status: granted. Granted Jun 4, 2019. Expires May 30, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K35/30, A61K35/545, A61P, A61P27/02, A61P27/06
More from Astellas Institute for Regenerative Medicine
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 10307444?
US 10307444 (Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells) is held by Astellas Institute for Regenerative Medicine. Status: granted. Granted Jun 4, 2019. Expires May 30, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10307444?
Astellas Institute for Regenerative Medicine is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 10307444 expire?
Our index shows an expiration date of May 30, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.